Roxithromycin versus penicillin in the treatment of erysipelas in adults: a comparative study.

A prospective, randomized, multicentre trial was conducted to evaluate the efficacy and safety of roxithromycin (150 mg b.i.d. orally) and penicillin (2.5 MU x 8 daily intravenously, then 6 MU daily orally) in the treatment of hospitalized adult patients with erysipelas. Seventy-two patients entered the study. Thirty-one patients in the roxithromycin group and 38 patients in the penicillin group completed the trial. The overall efficacy rates (cure without additional antibiotics) were 84% (26/31) in the roxithromycin group and 76% (29/38) in the penicillin group (P = 0.43). No side-effects were observed in the roxithromycin-treated patients whereas rashes occurred in two cases in the penicillin group, leading to exclusion from the study. Oral roxithromycin can thus be considered an effective and well-tolerated treatment for erysipelas in adult hospitalized patients.
AuthorsP Bernard, P Plantin, H Roger, B Sassolas, E Villaret, V Legrain, J C Roujeau, Y Rezvani, A Scheimberg
JournalThe British journal of dermatology (Br J Dermatol) Vol. 127 Issue 2 Pg. 155-9 (Aug 1992) ISSN: 0007-0963 [Print] ENGLAND
PMID1390144 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Penicillins
  • Roxithromycin
  • Acute Disease
  • Adult
  • Aged
  • Aged, 80 and over
  • Erysipelas (drug therapy, microbiology)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Penicillins (therapeutic use)
  • Prospective Studies
  • Roxithromycin (therapeutic use)
  • Staphylococcus aureus (isolation & purification)
  • Streptococcus (isolation & purification)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: